HillemanDE, MohiuddinSM, LucasBDJr.Nonsteroidal antiinflammatory drug use in patients receiving warfarin: emphasis on nabumetone. Am J Med1993; 95(suppl 2A):30S–4S.
2.
MortensenME, RennebohmRM. Clinical pharmacology and use of nonsteroidal anti-inflammatory drugs. Pediatr Clin North Am1989; 36: 1113–39.
3.
VerbeekRK. Pharmacokinetic drug interactions with nonsteroidal antiinflammatory drugs. Clin Pharmacokinet1990; 19: 44–66.
4.
SerlinMJ, BreckenridgeAM. Drug interactions with warfarin. Drugs1983; 25: 610–20.
5.
PullarT, CapellHA. Interaction between oral anti-coagulant drugs and non-steroidal anti-inflammatory agents: a review. Scott Med J1983; 28: 42–7.
6.
LewisRJ, TragerWF, ChanKK, BreckenridgeA, OrmeM, RolandMWarfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest1974; 53: 1607–17.
7.
SansomLN, EvansAM. What is the true clinical significance of plasma protein binding displacement interactions?Drug Saf1995; 12: 227–33.
8.
ShorrRI, RayWA, DaughertyJR, GriffinMR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med1993; 153: 1665–70.
9.
BuckleyNA, DawsonH.Drug interactions with warfarin. Med J Aust1992; 157: 479–83.
10.
MacKichanJJ. Pharmacokinetic consequences of drug displacement from blood and tissue proteins. Clin Pharmacokinet1984; 9(suppl 1):32–41.
11.
SellersEM. Plasma protein displacement interactions are rarely of clinical significance. Pharmacology1979; 18: 225–7.
12.
du SouichP, VergesJ, ErillS.Plasma protein binding and pharmacological response. Clin Pharmacokinet1993; 24: 435–40.
13.
BesunderJB, ReedMD, BlumerJL. Principles of drug biodisposition in the neonate: a critical evaluation of the pharmacokinetic-pharmacodynamic interface (part 1). Clin Pharmacokinet1988; 14: 189–216.
14.
YedinakKC, SproatTT. Heparin and warfarin therapy after acute myocardial infarction. Clin Pharm1993; 12: 197–215.
15.
BanfieldC, O'ReillyR, ChanE, RowlandM.Phenylbutazone–warfarin interaction in man: further stereochemical aspects and metabolic considerations. Br J Clin Pharmacol1983; 16: 669–75.
16.
Koch-WeserJ, SellersEM. Drug interactions with coumarin anticoagulants: part 1. N Engl J Med1971; 285: 487–98.
17.
NunnB, ChamberlainPD. Effect of nabumetone (BRL 14777), a new anti-inflammatory drug on human platelet activity ex vivo: comparison with naproxen. J Pharm Pharmacol1982; 34: 576–9.
18.
HochbergMC. Association of nonsteroidal antiinflammatory drugs with upper gastrointestinal disease: epidemiologic and economic considerations. J Rheumatol1992; 19(suppl 36):63–7.
19.
CarusoI, PorroGB. Gastroscopic evaluation of anti-inflammatory agents. Br Med J1980; 280: 75–8.
20.
ChowWH, CheungKL, LingHM, SeeT.Potentiation of warfarin anticoagulation by topical methylsalicylate ointment. J R Soc Med1989; 82: 501–2.
21.
YipASB, ChowWH, TaiYT, CheungKL. Adverse effect of topical methylsalicylate ointment on warfarin anticoagulation: an unrecognized potential hazard. Postgrad Med J1990; 66: 367–9.
